Want to see HOWL full AI Analyst Report?
Top Page
Werewolf Therapeutics
(NASDAQ:HOWL)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.40
▼(-6.05% Downside)
Action:Reiterated
Date:08/05/26
The score is primarily weighed down by weak financial performance—large ongoing losses, sustained negative free cash flow, and a shrinking equity/asset base that can increase future funding risk. Technicals add some support with the stock slightly above short-term moving averages and neutral momentum, but the longer-term trend remains pressured. Valuation contributes negatively due to the loss-making profile (negative P/E) and no dividend yield support.
Positive Factors
Differentiated platform
Werewolf’s conditionally activated cytokine platform is a durable competitive asset in immuno-oncology. Tumor-localized activation can materially improve therapeutic index versus systemic cytokines, supporting differentiated clinical value, easier partnership conversations, and long-term product-market fit if clinical proof emerges.
Negative Factors
High cash burn
Persistently negative operating and free cash flow (~-$30M TTM) is a durable constraint: it forces reliance on financings or milestone receipts to support trials and operations, increases dilution risk, and can slow program timelines if fresh capital is delayed over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated platform
Werewolf’s conditionally activated cytokine platform is a durable competitive asset in immuno-oncology. Tumor-localized activation can materially improve therapeutic index versus systemic cytokines, supporting differentiated clinical value, easier partnership conversations, and long-term product-market fit if clinical proof emerges.
Read all positive factors
Werewolf Therapeutics (HOWL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.67M
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)1.96
Revenue GrowthN/A
EPS Growth55.37%
CountryUS
Employees39
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.73
Shares Outstanding48,599,068
10 Day Avg. Volume1,746,006
30 Day Avg. Volume1,221,642
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.48
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.89
Revenue Forecast (FY)N/A
Werewolf Therapeutics Business Overview & Revenue Model
Company Description
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecul...
How the Company Makes Money
Werewolf Therapeutics generates revenue primarily through collaboration and license arrangements common to clinical-stage biotech companies. These agreements can include upfront payments, research and development reimbursements or service revenue,...
Werewolf Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.00M | 0.00 | 1.89M | 19.94M | 16.40M | 0.00 |
| Gross Profit | 18.15M | -1.63M | 71.00K | 18.18M | 13.89M | 0.00 |
| EBITDA | -22.02M | -53.91M | -64.05M | -32.47M | -51.30M | -49.77M |
| Net Income | -34.61M | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M |
Balance Sheet | ||||||
| Total Assets | 24.16M | 69.40M | 126.93M | 174.83M | 160.25M | 179.25M |
| Cash, Cash Equivalents and Short-Term Investments | 21.99M | 57.95M | 111.00M | 134.34M | 129.31M | 157.53M |
| Total Debt | 0.00 | 9.44M | 37.09M | 51.92M | 14.68M | 15.66M |
| Total Liabilities | 7.86M | 44.59M | 53.54M | 63.46M | 37.91M | 26.46M |
| Stockholders Equity | 16.29M | 24.80M | 73.39M | 111.37M | 122.34M | 152.79M |
Cash Flow | ||||||
| Free Cash Flow | -30.15M | -60.29M | -56.44M | -33.38M | -44.21M | -43.37M |
| Operating Cash Flow | -30.15M | -60.29M | -56.19M | -32.61M | -40.60M | -42.88M |
| Investing Cash Flow | 416.00K | 0.00 | -254.00K | -769.00K | -3.61M | -498.00K |
| Financing Cash Flow | -26.77M | 6.03M | 13.08M | 58.43M | 15.91M | 109.43M |
Werewolf Therapeutics Technical Analysis
Positive
0.43
Price Trends
0.38
Positive
0.55
Negative
0.68
Negative
Market Momentum
<0.01
Positive
51.28
Neutral
43.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOWL, the sentiment is Positive. The current price of 0.43 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.38, and below the 200-day MA of 0.68, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.28 is Neutral, neither overbought nor oversold. The STOCH value of 43.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOWL.
Werewolf Therapeutics Risk Analysis
Werewolf Therapeutics disclosed 87 risk factors in its most recent earnings report. Werewolf Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Werewolf Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $341.38M | -2.44 | -314.08% | ― | 40.21% | 13.40% | |
48 Neutral | $137.15M | -4.40 | 168.68% | ― | ― | 67.07% | |
46 Neutral | $41.28M | -0.85 | -156.02% | ― | -95.74% | -23.18% | |
45 Neutral | $19.67M | -0.55 | -208.23% | ― | ― | 55.37% | |
44 Neutral | $89.11M | -2.02 | -71.71% | ― | ― | 73.44% |
* Healthcare Sector Average
HOWL
Werewolf Therapeutics
0.40
-0.93
-69.62%
CRVO
CervoMed
2.73
-7.10
-72.23%
NRXP
NRX Pharmaceuticals
3.27
0.51
18.48%
KLRS
Kalaris Therapeutics
4.08
1.58
63.20%
CAMP
CAMP4 Therapeutics Corporation
5.44
3.58
192.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.